Cardium Therapeutics is a health sciences and regenerative medicine company building a portfolio of bio-medical opportunities and businesses with a definable pathway to commercialization and the potential to revolutionize the healthcare industry by meeting unmet medical needs.
The company’s flagship product is Excellagen®, a topical gel for wound care management packaged in a ready-to-use, pre-filled, single use syringe. The gel is designed to activate human platelets, triggering the release of platelet-derived growth factor (PDGF) – in layman’s terms, the gel accelerates the growth of granulation tissue, activating the wound healing process. With this capability, the product has a wide range of applications in the healthcare industry.
Excellagen is used by healthcare professionals to manage diabetic ulcers and other dermal wounds such as pressure, venous, and chronic vascular ulcers; surgical wounds; trauma wounds such as abrasions, lacerations, second-degree burns, and skin tears; and draining wounds.
Having been cleared by the U.S. Food and Drug Administration for marketing and sale of the product in the United States, Cardium is now looking for partners to market and sell the product both domestically and abroad.
Cardium plans to obtain a CE Mark to market Excellagen in the 27 member countries of the European Union, and has already established a distribution agreement with BL&H Co. for Excellagen in South Korea. For further international market penetration, Cardium has partnered with Advanced Biosciences Research to commercialize Excellagen in Russia and the eight member countries comprising the Commonwealth of Independent States (CIS).
As it seeks out avenues to launch Excellagen onto the global scene, Cardium is also working on building out its product line. The company sees Excellagen as a base platform from which to build a new portfolio of advanced wound care and therapeutic products.
Cardium’s Gene Activated Matrix (GAM) technology is an extension of Excellagen’s viscosity optimized, fibrillar collagen-based matrix for the localized topical delivery of agents that potentially could include anti-infectives, antibiotics, peptides, proteins, small molecules, DNA, stem cells, differentiated cells, and conditioned cell media.
The company’s initiatives for Excellagen echo the broader business model to create multiple opportunities for success without relying on any single technology. The company continues to seek out cost-effective acquisitions to add to its current portfolio, which also includes To Go Brands, a healthy nutraceutical supplement business, the Tissue Repair Company, and Cardium Biologics.
For more information, visit www.cardiumthx.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
